Gosh, it’s been a busy few weeks! Our news cycle has been dominated by Lykos Therapeutics-related stories, from ICER’s report and panel meeting through to FDA’s Advisory Committee meeting and yesterday’s patent-related news. Elsewhere in the psychedelics field, things have been a little quieter; especially for this author who was unable to attend the sixth edition of the Interdisciplinary…


Previous articleBreaking: Lykos Therapeutics Moved to Patent MDMA In Late 2022, Filing Reveals
Next articleCommunity, Group Process, and Co-Creation: How to Build a Successful Retreat